Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2013

BMS Licenses PeptiDream Technology, Extends Collaboration

  • PeptiDream said today it agreed to license nonexclusively its Peptide Discovery Platform System (PDPS) technology to Bristol-Myers Squibb (BMS), as well as to a second extension of a related collaboration—a nearly three-year-old macrocyclic peptide drug discovery alliance—with the pharma giant.

    The value of the PDPS deal was undisclosed, though PeptiDream said BMS agreed to pay up-front and annual technology access payments as well as potential  additional payments tied to development milestones and royalties on future sales of products arising from PDPS.

    “The PDPS technology license was based on the successes achieved during the first three years of our discovery collaboration with Bristol-Myers Squibb,” PeptiDream CEO Kiichi Kubota said in a statement.

    That collaboration was launched Oct. 15, 2010, then extended last Oct. 15. On Feb. 15 and again March 15, PeptiDream said it received undisclosed payments for achieving milestones with BMS—the latter following the identification of a lead compound.

    Today, PeptiDream said, it joined BMS in signing a second extension of two years, through October 2015, under which PeptiDream will continue to use PDPS for translational synthesis, selection, and screening of nonstandard macrocyclic peptides for identification as potential drug candidates for BMS targets.

    BMS will own all rights to lead peptides and will be responsible for all subsequent research and development as pharmaceutical candidates. In return, PeptiDream will continue to receive from BMS undisclosed research funding; potential payments tied to additional undisclosed development milestones; and royalties on future sales from products developed through the collaboration.

    Kubota added that the second extension of PeptiDream’s discovery partnership with BMS “will allow both companies to continue our mutual efforts to drive a number of exciting macrocyclic peptide programs into the clinic in both the United States and Japan.”

    He said the PDPS up-front payment, annual technology access payments, and extended collaboration funding “will significantly contribute to PeptiDream’s revenue, starting from this fiscal year,” while the potential milestone payments and royalties “offer the possibility of revenues far into the future.”


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »